- Home
- SCYX vs CLPS Comparison
SCYX vs CLPS Comparison
Compare SCYX & CLPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- CLPS
- Stock Information
- Founded
- SCYX 1999
- CLPS 2005
- Country
- SCYX United States
- CLPS Hong Kong
- Employees
- SCYX N/A
- CLPS N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- CLPS Computer Software: Prepackaged Software
- Sector
- SCYX Health Care
- CLPS Technology
- Exchange
- SCYX Nasdaq
- CLPS Nasdaq
- Market Cap
- SCYX 28.5M
- CLPS 26.0M
- IPO Year
- SCYX 2014
- CLPS 2018
- Fundamental
- Price
- SCYX $0.75
- CLPS $0.99
- Analyst Decision
- SCYX
- CLPS
- Analyst Count
- SCYX 0
- CLPS 0
- Target Price
- SCYX N/A
- CLPS N/A
- AVG Volume (30 Days)
- SCYX 145.5K
- CLPS 12.3K
- Earning Date
- SCYX 08-07-2025
- CLPS 03-05-2025
- Dividend Yield
- SCYX N/A
- CLPS 13.35%
- EPS Growth
- SCYX N/A
- CLPS N/A
- EPS
- SCYX N/A
- CLPS N/A
- Revenue
- SCYX $2,630,000.00
- CLPS $153,816,045.00
- Revenue This Year
- SCYX $463.61
- CLPS N/A
- Revenue Next Year
- SCYX $310.80
- CLPS N/A
- P/E Ratio
- SCYX N/A
- CLPS N/A
- Revenue Growth
- SCYX N/A
- CLPS 5.81
- 52 Week Low
- SCYX $0.66
- CLPS $0.68
- 52 Week High
- SCYX $2.29
- CLPS $1.70
- Technical
- Relative Strength Index (RSI)
- SCYX 38.69
- CLPS 45.57
- Support Level
- SCYX $0.67
- CLPS $0.90
- Resistance Level
- SCYX $0.75
- CLPS $0.94
- Average True Range (ATR)
- SCYX 0.04
- CLPS 0.04
- MACD
- SCYX 0.00
- CLPS -0.00
- Stochastic Oscillator
- SCYX 33.06
- CLPS 38.46
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About CLPS CLPS Incorporation
CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.